Targeting angiogenesis is a promising strategy for cancer therapy because it aims to "starve" the tumor by cutting off its blood supply. Drugs known as anti-angiogenic agents can inhibit the action of pro-angiogenic factors, effectively slowing down or halting tumor growth. Bevacizumab (Avastin), a monoclonal antibody against VEGF, is one example of such a therapeutic agent.
